The Pfizer and AstraZeneca coronavirus vaccines are highly effective against the variant identified in India after two doses, a study has found.
Two jabs of either vaccine give a similar level of protection against symptomatic disease from the Indian variant as they do for the Kent one.
However, both vaccines were only 33% effective against the Indian variant three weeks after the first dose.
This compared with 50% effectiveness against the Kent variant.
Public Health England, which ran the study, said the vaccines are likely to be even more effective at preventing hospital admission and deaths.
Health Secretary Matt Hancock said the findings made him "increasingly confident" that the government was on track for the final stage of easing restrictions in England on 21 June.
The data showed that getting both doses of the vaccine was "absolutely vital", he added.
Home Secretary Priti Patel said the data on the two vaccines was "positive" but the government's planned "stages" for further easing of restrictions still needed to be followed.
She told the BBC's Andrew Marr Show: "We will continue to follow the data... we all have to be conscientious. All of us that are out and about now, we are distancing, wearing masks, following all the rules.
"That is part of our normal life now and that will continue, and that, of course, will help us to that unlocking on 21 June."
Questioned about criticism of the timing of putting India on the travel red list, the home secretary said ministers "work with the data... and that information was presented to ministers in the right way for the decisions to be made".
'Get your second dose'
The Pfizer vaccine was found to be 88% effective at stopping symptomatic disease from the Indian variant two weeks after the second dose, compared with 93% effectiveness against the Kent variant.
The AstraZeneca jab was 60% effective against the Indian variant, compared with 66% against the Kent variant.
Public Health England (PHE) said the difference in effectiveness between the vaccines after two doses might be explained by the fact that rollout of second doses of AstraZeneca was later than for the Pfizer vaccine, which was approved first.
Other data shows it takes longer to reach maximum effectiveness with the AstraZeneca vaccine, PHE said.
Some 12,675 genome-sequenced cases were included in the study, which took place between 5 April and 16 May. Only 1,054 of those cases were of the Indian variant, known as B.1.617.2.
Dr Jenny Harries told the Andrew Marr Show the study was "very good news".
The chief executive of the UK Health Security Agency said the study is the "first real-world evidence of vaccine effectiveness" against the variant, showing the vaccine is just as effective after two doses as it has been against the Kent variant.
"The straightforward message is 'get your second dose'," she added.
Asked about the discrepancy between the Pfizer and AstraZeneca vaccine results, she said a key factor to consider was that the "different vaccines were given to slightly different groups of people".
"The Pfizer vaccine was rolled out initially, because it had to be kept at ultra-low temperatures, to - for example - healthcare workers, who tended to be younger," she said.
"This is an all-age study. Whereas AstraZeneca went out to older groups of individuals who were unable to come into main centres."
She stressed that "both of these vaccines are really good" and there will be more refinement of the data.
'Very reassuring'
As the virus changes, protection against infection was always going to be the first thing that slips.
So the fact that the Pfizer and AstraZeneca vaccines offer such a high degree of protection against the Indian variant after the second dose is very reassuring given experts expect it to become dominant.
But what are the implications of the drop in effectiveness of the first dose where the Indian variant is concerned?
Given it's expected to become the dominant variant in the UK, it's now even more important people get their second jab.
The more difficult question to answer is what this means for the speed of the route back to normality.
Its ability to evade the vaccines even by a small degree will be a factor in how more transmissible this variant is here.
There are also other biological reasons why it might find it easier to spread.
But this does not necessarily mean we will see a surge in cases and, crucially, hospital admissions - the protection vaccines give us against serious illness will be much much higher than their ability to block mild infections.
The Indian variant certainly gives the virus a bit more of an advantage, but it doesn't mean the vaccines won't win out.
The study looked at data from all age groups from 5 April, to cover the period since the Indian variant emerged.
There is not enough data to estimate how effective the vaccine is against severe outcomes for the Indian variant, PHE said.
Dr Jamie Lopez Bernal, consultant medical epidemiologist at PHE and the study's lead author, said there was higher confidence in the data from the first vaccine dose than that from the second.
He said: "There are bigger numbers that have been vaccinated with one dose. So I think we classify that as moderate certainty around the first dose, but low levels of confidence around the second dose."
However, Prof Susan Hopkins, PHE's Covid-19 strategic response director, said the data trend was "quite clear" and was heading in the "right direction".https://emp.bbc.com/emp/SMPj/2.42.4/iframe.htmlmedia captionWhy do new variants of Covid-19 keep appearing? Laura Foster explains
Meanwhile, Gordon Brown has urged Prime Minister Boris Johnson to use next month's G7 summit in Cornwall to step up funding of the global Covid vaccine rollout.
In an interview for BBC Radio 4's The World This Weekend, the former prime minister said what rich countries had given so far would not meet the needs of this year and next year.
In other news, more than 50 million coronavirus vaccine doses have now been given in England. More than 31 million people have had their first jab, and over 18m have had their second.
Some 13,000 deaths and 39,100 hospitalisations have been prevented in the UK due to the vaccination programme up to 9 May, according to PHE analysis.
Latest Stories
-
CLOGSAG vows to resist partisan appointments in Civil, Local Government Service
12 minutes -
Peasant Farmers Association welcomes Mahama’s move to rename Agric Ministry
13 minutes -
NDC grateful to chiefs, people of Bono Region -Asiedu Nketia
16 minutes -
Ban on smoking in public: FDA engages food service establishments on compliance
16 minutes -
Mahama’s administration to consider opening Ghana’s Mission in Budapest
18 minutes -
GEPA commits to building robust systems that empower MSMEs
21 minutes -
Twifo Atti-Morkwa poultry farmers in distress due to high cost of feed
23 minutes -
Central Region PURC assures residents of constant water, power supply during yuletide
24 minutes -
Election victory not licence to misbehave – Police to youth
26 minutes -
GPL 2024/2025: Nations thrash struggling Legon Cities
28 minutes -
Electoral offences have no expiry date, accountability is inevitable – Fifi Kwetey
29 minutes -
Ghanaians to enjoy reliable electricity this Christmas – ECG promises
36 minutes -
Police deny reports of election-related violence in Nsawam Adoagyiri
39 minutes -
‘We’re not brothers; we’ll show you where power lies’ – Dafeamekpor to Afenyo-Markin
43 minutes -
EPA says lead-based paints are dangerous to health, calls for safer alternatives
3 hours